Quarterly report pursuant to Section 13 or 15(d)

Discontinued Operations

v3.21.2
Discontinued Operations
6 Months Ended
Jun. 30, 2021
Discontinued Operations  
Discontinued Operations

9.    Discontinued Operations

The components of loss from discontinued operations as reported in our condensed statements of operations and comprehensive loss were as follows:

    

Three Months Ended

Six Months Ended

June 30, 2020

June 30, 2020

 

(In thousands, except per share data)

Revenue:

 

  

Product revenue

$

76

$

286

Costs and expenses:

 

  

 

Cost of goods sold

 

228

 

399

Research and development

 

363

 

828

Selling, general and administrative

 

2,251

 

4,077

Total costs and expenses

 

2,842

 

5,304

Loss from discontinued operations

 

(2,766)

 

(5,018)

Other expense, net

 

 

Net loss from discontinued operations

$

(2,766)

$

(5,018)

Basic and diluted net loss per common share from discontinued operations

$

(0.87)

$

(1.70)

Weighted average shares used in computing basic and diluted net loss per common share

 

3,165

 

2,960

The following table presents information related to assets and liabilities reported as discontinued operations in our condensed balance sheets:

June 30, 

    

December 31,

    

2021

    

2020

(In thousands)

  

 

  

Prepaid expenses and other current assets

$

70

$

181

Discontinued operations – current assets

$

70

$

181

Accounts payable

$

1,249

$

1,515

Accrued clinical trials expenses

 

25

 

80

Accrued sales allowances

 

 

61

Other accrued liabilities

 

353

 

304

Discontinued operations – current liabilities

$

1,627

$

1,960

During the three and six months ended June 30, 2020 we recognized non-cash stock-based compensation expenses of approximately $77,000 and $101,000, respectively, which is included in discontinued operations.